Evidence map›Paper›PMID 26676826›Full record

ArticleJournal of neurovirology2016

Predictors and characteristics of seizures in survivors of progressive multifocal leukoencephalopathy.

Dhanashri P Miskin, Susan T Herman, Long H Ngo, Igor J Koralnik

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neurovirology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. JC Virus Infects Neurons and Glial Cells in the Hippocampus.Journal of neuropathology and experimental neurology · 2016
    Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Dhanashri P MiskinDivision of Neuro-Immunology, Department of Neurology, Center for Virology and Vaccine Research, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Harvard University, Boston, MA, USA. dmiskin@bidmc.harvard.edu.
Susan T HermanDivision of Epilepsy, Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Harvard University, Boston, MA, USA.
Long H NgoDivision of General Medicine and Primary Care Section for Research, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Harvard University, Boston, MA, USA.
Igor J KoralnikDivision of Neuro-Immunology, Department of Neurology, Center for Virology and Vaccine Research, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Harvard University, Boston, MA, USA.
Harvard University · USBeth Israel Deaconess Medical Center · US

Funding

Role of Inflammation in Progressive Multifocal LeukoencephalopathyR01NS047029 · NINDS · RUSH UNIVERSITY MEDICAL CENTER · PI KORALNIK, IGOR J. · 2004 to 2018
$6.4M
Pathogenesis of a JC Virus Variant in Pyramidal NeuronsR01NS074995 · NINDS · RUSH UNIVERSITY MEDICAL CENTER · PI KORALNIK, IGOR J. · 2012 to 2016
$1.8M
NINDS NIH HHS R01 NS047029NINDS NIH HHS R01 NS074995
6 · The paper itself

Abstract

This study aims to determine the risk factors for epileptogenesis and characteristics of seizures in patients with progressive multifocal leukoencephalopathy (PML) who survive more than 1 year from onset of neurological symptoms (PML survivors). We reviewed clinical data including seizure history and MR imaging studies from PML survivors evaluated at our institution between 1997 and 2014. PML progressors who passed away within 1 year and patients with a history of seizures prior to PML diagnosis were excluded from the analysis. Of 64 PML survivors, 28 (44 %) developed seizures. The median time from the onset of PML symptoms to the first seizure was 5.4 months (range 0-159) and 64 % of patients with seizures had them within the first year. The presence of juxtacortical PML lesions was associated with a relative risk of seizures of 3.5 (p < 0.02; 95 % confidence interval (CI) 1.3-9.4) in multivariate analyses. Of all seizure types, 86 % were focal and 60 % most likely originated from the frontal lobes. Among seizure patients, 89 % required treatment, including one (54 %), two (25 %), or three (10.5 %) antiepileptic drugs. Seizures are a frequent complication in PML and can develop throughout the entire course of the disease. However, late onset seizures did not signify PML relapse. Seizures may require treatment with multiple antiepileptic medications and are a significant co-morbidity in PML.

Indexed as

SurvivorsAdultAgedAged, 80 and overAnticonvulsantsBrainBrain MappingDisease ProgressionFemaleHumansJC VirusLeukoencephalopathy, Progressive MultifocalMagnetic Resonance ImagingMaleMiddle AgedPrognosisAnticonvulsantsEpilepsyJC virusProgressive multifocal leukoencephalopathySeizuresSurvivors

Identifiers

PMID26676826
PMCPMC4937716
OpenAlexW2198623579

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.